- Home
- XOS vs MRKR Comparison
XOS vs MRKR Comparison
Compare XOS & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XOS | MRKR |
|---|---|---|
| Founded | 2016 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Construction/Ag Equipment/Trucks | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.5M | 16.6M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | XOS | MRKR |
|---|---|---|
| Price | $2.15 | $2.06 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $7.00 | ★ $10.17 |
| AVG Volume (30 Days) | 43.2K | ★ 359.0K |
| Earning Date | 11-13-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $52,246,000.00 | $4,694,988.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $25.72 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.74 | $0.81 |
| 52 Week High | $9.15 | $4.07 |
Technical Indicators
Market Signals| Indicator | XOS | MRKR |
|---|---|---|
| Relative Strength Index (RSI) | 51.81 | 73.26 |
| Support Level | $1.74 | $1.45 |
| Resistance Level | $2.15 | $1.55 |
| Average True Range (ATR) | 0.13 | 0.16 |
| MACD | 0.03 | 0.07 |
| Stochastic Oscillator | 89.04 | 66.94 |
Price Performance
Historical ComparisonAbout XOS Xos Inc.
Xos Inc is a fleet electrification solutions provider committed to the decarbonization of commercial transportation. Xos designs and manufactures Classes 5 through 8 battery-electric commercial vehicles that travel on last-mile, back-to-base routes of up to 200 miles per day. Xos also offers charging infrastructure products and services through Xos Energy Solutions to support electric vehicle fleets. Its products include Stepvan, MDXT, HDXT, Xosphere, and Xos Energy Solutions.
About MRKR Marker Therapeutics Inc.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.